ArticleBMC microbiology2025
The control of mushroom pathogen Lecanicillium fungicola with fungicides and Bacillus-based biocontrol treatments during crop trial studies.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLecanicillium fungicola is a fungal pathogen of the white button mushroom (Agaricus bisporus) and causes dry bubble disease. Due to the recent withdrawal of approval for the most common fungicide prochloraz, only one approved fungicide, metrafenone can be used on mushroom crops within the European Union. Biocontrol uses antagonist bacteria and is being evaluated as a sustainable alternative to fungicides. Bacillus velezensis (QST 713) is the active agent in a commercially available biocontrol product, while B. velezensis (Kos) is a novel strain. Both have shown antagonistic activity against L. fungicola in vitro. The aim of this work was to evaluate the management of dry bubble disease during large scale crop trials using both fungicide and biocontrol treatments and using a range of inoculation levels to establish a level which best reflects on-farm conditions.
resultsAn inoculation rate of 1 × 10
conclusionThis work provides important information to the mushroom sector on the treatment of dry bubble disease and provides suggestions to researchers when considering inoculation levels to include for testing biocontrol treatments at a crop level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.